by Richard Daverman, PhD
April 6, 2013 -- Sanofi is actively seeking China M&A opportunities in the consumer healthcare and veterinary products sectors, according to the company’s CEO; Jiangsu Hengrui Medicine in-licensed China rights to a novel antibody from X-Body Biosciences of the US; Sanofi Pasteur will fund research at China’s Xiamen University aimed at developing a universal flu vaccine; Baxter’s China division announced a program with China officials to bring home-based kidney dialysis to China’s rural areas; China NT Pharma Group signed a MOU with Sinopharm to form a JV that will market and sell vaccines; Hangzhou Nurotron Biotech has developed a cochlear implant at half the current price; and a new strain of bird flu, H7N9, in China has mobilized the CDC. More details…..
Stock Symbols: (NYSE: SNY) (SHA: 600276) (NYSE: BAX) (HK: 01011) (HK: 01099)
